Spotlight on Canada at #BIO2016

BIO LogoThe BIO 2016 conference offers an opportunity for the best and brightest minds in biotechnology to gather together and exchange ideas. Here at Lilly, we’re excited for the conversations that will happen at BIO, particularly those focused on improving health care.

Are you interested in learning more about advances in biotechnology? Don’t miss these BIO 2016 events featuring Canadian leaders in the health care industry:

June 6: The Newest Bright Shiny Thing -- The Challenge Of True Innovation

At Lilly, we believe that innovation lies at the heart of drug discovery. But what does it really mean to be an “innovative” company in the life sciences sector? That’s the focus of this panel discussion featuring William Charnetski, Ontario’s Chief Health Innovation Strategist.

June 7: Clinical Trials – The Canadian Advantage

Don’t miss the Canadian Clinical Trials Coordinating Centre’s panel on the clinical trials environment in Canada. Panelists are set to discuss “how Canada can further improve its competitiveness as a destination to conduct clinical trials.” For some pre-reading, check out CCTCC’s report outlining recommendations for strengthening and streamlining the clinical trial process in Canada.

June 8: Patient-Centered Initiatives: Opportunities for Global Rare Disease Policy Development

Nearly 1 in 12 Canadians currently live with a rare disease. This session will focus on the global rare disease policy environment and will feature Dr. Durhane Wong-Rieger, President and CEO of the Canadian Organization for Rare Disorders (CORD). Last year, CORD oversaw the release of the first ever Canadian Rare Disease Strategy, aimed at improving the lives of Canadians living with rare disease.

Follow #BIO2016 to keep up-to-date on all the top moments from San Francisco!

/WP/wp-content/uploads/sidebar_GDOS7.jpg
/WP/wp-content/uploads/canada_charting_the_course.jpg
/WP/wp-content/uploads/canada_size_up.jpg
/WP/wp-content/uploads/canada_wip.jpg